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Recent advances in acute pain mechanisms and
management have implicated the N-methyl d-
aspartate receptor-ion channel complex in the
development of postoperative hyperalgesia and acute
opiod tolerance. l/-methyl d-aspartate receptor
antagonists such as ketamine have been used
increasingly in clinical studies in an effort to
minimize acute postoperative pain and reduce opiod
requirements. A mixture of ketamine and an opiod
administered in the same solution and syringe would
be a practical and useful technique for postoperative
epidural analgesia, continuous IV infusion, or
patient-controlled IV analgesia. We investigated
the stability of a morphine sulfate and racemic
ketamine solution in saline at pH 5.5-7.5 over a
period of 4 days. Our study demonstrates that the
ketamine morphine mixture at a clinically relevant
concentration seems to be stable at room
temperature, at a wide range of pH values, for at
least 4 days.
Au*** in the understanding of acute pain
mechanisms have led to a renaissance of the use of
ketamine hydrochloride because of its actions as an N-
methyl d-aspartate receptor antagonist (1). Clinical studies
have reported improved pain relief using ketamine as an
adjunct to various analgesics in the treatment of acute
postoperative pain(2-5) and cancerpain (6).
Of particular interest is the combination of smalldose
ketamine with opioids, the most commonly used drugs for
postoperative pain relief. In the clinical setting,
subanesthetic doses of ketamine administered with opioids
reduced opioid requirements and opioidrelated adverse
effects (2,1 ,8) perhaps because of the ability of small-dose
N-methyl d-aspartate antagonists to interfere with the
development of acute opioid tolerance (9) and opioid-
induced hyperalgesia (10,1 l).
A mixture of ketamine and an opioid administered
in the same solution and syringe would be a practical and
useful technique for postoperative epidural analgesia,
continuous IV infusion, or patient-controlled IV analgesia.
However, to administer such a mixture of drugs safely to
the patient over a period of several days, one must ensure
that the mixture demonstrates physical and chemical
stability. Because morphine is the most frequently used
opioid for the treatment of acute and chronic pain, we
investigated the stability of a morphine sulfate and racemic
ketamine solution in saline at pH 5.5-7.5 over a period of 4
days.
Materials and Methods
To prepare the stock solutions, the following materials
were used: | 20-nL vial of ketamine hydrochloride
(Ketalaro; Parke-Davis, Scarborough, ON, Canada)
containing 10 mg/ml ketamine; 2t-ml- vials of morphine
sulfate 15 mg/ml (Abbott Laboratories, Ltd., Saint-
Laurent, QC, Canada);2L-mL vials of morphine sulfate l0
mglmL (Abbott Laboratories); I l-ml- vial of morphine
sulfate 2 mglmL (Abbott Laboratories); NaCl, NaOH l0 N,
HCI 6 N (Fisher Scientihc Ltd., Nepean, ON, Canada).
A stock solution of 0.9% NaCl was prepared in water; 50
mL was aliquoted, and the pH of each aliquot was adjusted
to 5.5, 6.0, 6.5, 7.0, and 7.5. The ketamine and morphine
were mixed together in the saline at pH 5.5-7.5 at a final
concentration of 1.33 mglmL for ketamine and 2.0 mg/mL
for morphine. The total volume of the solution was 25 mL.
As soon as the mixtures were ready, 6 1.0-mL aliquots
were taken and kept at 20"C in Falcon polystyrene tubes
until analysis. The remaining solution was kept at room
temperature, also in Falcon polystyrene ubes, for the
subsequent 4 days. Each day, the same exercise was
repeated: 1.0 mL was aliquoted in 6 small vials. They were
placed immediately at 20"C and kept there until analysis.
For ketamine analysis, a high-pressure liquid
chromatography (HPLC) method (12) was used with some
modifications. Briefly, the mobile phase was 0.1 M sodium
dihydrogen phosphate buffer pH 2.1 (adjusted with
phosphoric acid) containing I mM dodecyl sulfate and
22o/o acetonitrile. The flow rate was 0.8 mllmin and the
Table 1. Mean Ketamine and Morphine Concentrations and CV Across Days l-4 at pH 5.5-7.5
pH
7.s7.06.56.05.5
Ketamine
Mean concentration (mg/ml)
CV Days 1-4
Overall mean
CV pH 5.5-7.5
Morphine
Mean concentration (mg/ml)
CV Days 1*4
Overall mean
CVpH 5.5J.5
1.52i
2.348
1.49
9.40
2.485
2.181
2.362
7.905
1.445
3.874
2.336
4.454
1.391
1.048
t.345
3.385
1.525
1.614
2.26/,
1.226
2.1 88
3.091
2.317
t.666
CV 
_ 
coefficient ofvariation.
column was ProdigyrM ODS (3) 5 
_m, 150 _ 4.6 mm
(Phenomenex, Torrance, CA). We used a Shimadzu FIPLC
system equipped with a spechophotomehic detector set at
215 nn (Mandel Scientific, Guelph, ON, Canada). For
quantitation, a standard solution in saline was prepared
from the same Ketalar vial that was used for sample
preparation. For morphine analysis, the same HPLC
method was used. For quantitation, an aliquot from a new
vial of morphine sulfate 2 mg/ml- was used. In addition,
morphine was also measured in each sample by using an
enzyme-linked immunosorbent assay method. The
StatViewo SE program (SAS Institute Inc., Cary, NC) was
used for statistical analysis. The mean concentration of
ketamine and morphine was calculated each day. Within-
the-day and between-the-days coefficient of variation was
calculated for each compound.
Results and Discussion
Our study demonstrates that the ketamine-morphine
mixture at a clinically relevant concentration seems to be
stable at room temperature, at least for four days at a wide
range of pH (Table l). Initially, we examined the stability
of the solution at pH 5.5 only; however, although the
ketamine seemed to be very stable, the morphine results
were more erratic. There was no clear pattern of
concentration decrease in time, but the coefficient of
variation was rather high. The same pattern was observed
using both methods of analysis: I{PLC and enzyme-linked
immunosorbent assay. In the present stability study, we
therefore modified the original IIPLC method (12) by
adding an ion pairing agent to the mobile phase; the
ketamine results were unchanged, but the coefficient of
variation for morphine decreased considerably, from 11.04
to 2.18 at this particular pH (Table 1). There is some
indication in the literature (13) that, at pH higher than 5.9,
the mixture is no longer stable. However, in that study,
much larger concentrations (i.e., ketamine 41.2 mg/ml and
morphine 17.6 mg/mL) were used and the pH was adjusted
with sodium bicarbonate. We conclude that a ketamine-
morphine solution can be used at physiologic pH, at the
abovementioned concentrations and that it is stable for up
to four days at room temperature.
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